226 completed, 70 unknown, 7 recruiting, 5 not yet recruiting. 207 Phase 1, 39 Phase 4, 37 Phase 3, 21 Phase 2, 4 Not applicable.
Follow Chong Kun Dang Pharmaceutical: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers CKD-339, D311, D107 - Hypertension | Phase 1 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 76 | 2026-08-20 | 2026-08-06 |
| Comparison of the Incidence of Major Cardiovascular Events Between the Combination of Percutaneous Intervention and Optimal Drug Therapy and the Optimal Drug Therapy Alone in Patients With Chronic Coronary Syndrome percutaneous coronary intervention, Guideline-directed Optimal Medical treatment, Carvedilol Sustained-Release (SR) (Nested RCT subset) - Chronic Coronary Syndrome | Not applicable | Not yet recruiting | Seoul National University Hospital | 2301 | 2026-06-15 | 2026-06-12 |
| Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer CKD-215, D215 - Ovarian Cancer | Phase 1 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 24 | 2026-06-01 | 2026-04-15 |
| A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer CKD-703 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Chong Kun Dang Pharmaceutical | 140 | 2026-04-16 | 2026-04-27 |
| Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients empagliflozin 10mg, Glimepiride 1mg - Diabete Type 2 | Phase 4 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 200 | 2026-03-01 | 2026-01-26 |
| A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846 CKD-846, D091 - Benign Prostate Hypertrophy(BPH) | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 34 | 2026-02-23 | 2026-07-21 |
| A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants. CKD-706, US-Dupixent, EU-Dupixent - Atopic Dermatitis | Phase 1 | Recruiting | Chong Kun Dang Pharmaceutical | 519 | 2026-02-09 | 2026-01-23 |
| Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants SKYRIZI, CKD-704 - Psoriasis | Phase 1 | Recruiting | Chong Kun Dang Pharmaceutical | 213 | 2025-11-26 | 2025-12-19 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers CKD-383 0.25/12.5/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-30 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers CKD-383 0.5/10/1000mg, CKD-501, D744, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-28 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers CKD-383 0.5/25/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2025-10-24 | 2025-12-26 |
| Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors CKD-512, Pembrolizumab - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Recruiting | Chong Kun Dang Pharmaceutical | 60 | 2025-10-16 | 2026-02-02 |
| Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea Everolimus, Mycophenolate mofetil Tablet/Capsule - Heart Transplant | Phase 4 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 140 | 2025-08-14 | 2025-04-24 |
| A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants Midazolam, Rosuvastatin, CKD-508 Tablet - Healthy | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 24 | 2025-05-14 | 2026-02-27 |
| Initial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981 CKD-981(1), CKD-981(2), Sham device - Knee Osteoarthritis | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 100 | 2025-04-28 | 2026-04-13 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia CKD-843 dose#1, CKD-843 dose#2, Placebo of CKD-843 dose - Androgenetic Alopecia | Phase 3 | Recruiting | Chong Kun Dang Pharmaceutical | 288 | 2025-04-08 | 2026-09-03 |
| Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers D352, D794 - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 40 | 2024-11-27 | 2025-05-21 |
| A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants CKD-508 Tablet, Placebo Tablet - Healthy Subjects | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 44 | 2024-11-14 | 2026-02-27 |
| Clinical Study to Evaluate the Food Effect of CKD-378 in Healthy Volunteers CKD-378 25/1000mg - Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2024-11-08 | 2025-05-21 |
| Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy Volunteers CKD-383 - Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2024-11-06 | 2025-05-21 |
Showing 20 of 310. Sign in to see all of them.
Hypertension (58) · Diabetes Mellitus, Type 2 (52) · Dyslipidemias (41) · Essential Hypertension (18) · Cardiovascular Diseases (10) · Gastroesophageal Reflux (9) · Hyperlipidemias (8) · Prostatic Hyperplasia (7) · Hepatitis B, Chronic (6) · Angina, Stable (5) · Arthritis, Rheumatoid (5) · Heart Failure (5) · Alopecia (4) · Carcinoma, Non-Small-Cell Lung (4) · Glaucoma, Open-Angle (3)
lobeglitazone (33) · Atorvastatin (11) · Drug Evaluation (11) · Telmisartan (11) · levamlodipine (10) · Amlodipine (9) · CKD-519 (9) · Tablets (9) · Mycophenolic Acid (8) · candesartan (8) · Metformin (5) · Tacrolimus (5) · Capsules (4) · Darbepoetin alfa (4) · Fenofibrate (4)
South Korea (278) · United States (4) · Poland (2) · Russia (2) · United Kingdom (2) · Australia (1) · Czechia (1) · France (1) · Georgia (1) · Germany (1) · Netherlands (1) · Ukraine (1)
Jang Hee Hong (4) · Min-gul Kim (4) · Yook-Hwan Noh, M.D., PhD. (4) · Anhye Kim, Ph.D (3) · Ji Young Park, Ph.D. (3) · Min Soo Park, Ph.D (3) · Min Soo Park, Ph.D. M.D (3) · Min Soo Park, Ph.D. M.D. (3) · Young-Ran Yoon (3) · BongSoo Cha, Ph.D (2) · Eunyoung Kim (2) · Jaeseong Oh, M.D., Ph.D. (2) · Jaewoo Kim, M.D. (2) · Jaewoo Kim, M.D. Ph.D (2) · Jaewoo Kim, M.D., PhD. (2)
PMID 22721873, PMID 32362346, PMID 36791280, PMID 38771476, PMID 22697273, PMID 23187728, PMID 24060561, PMID 24337589, PMID 24736628, PMID 25047497, PMID 26163202, PMID 26767047, PMID 27460100, PMID 27566413, PMID 30569763, PMID 31564831, PMID 31992459, PMID 32468741, PMID 32994466, PMID 33099742, PMID 33191408, PMID 33246489, PMID 33829355, PMID 33953542, PMID 34010616, PMID 34723164, PMID 35227313, PMID 35730245, PMID 36342475, PMID 37034122, PMID 37042284, PMID 37043192, PMID 37181388, PMID 37742741, PMID 37821166, PMID 38065906, PMID 39513526, PMID 39602157, PMID 40251695, PMID 40255536, PMID 40623657, PMID 41366779, PMID 41453443, PMID 41672793, PMID 41921522, PMID 41970000
2025 (2)